These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19392611)

  • 1. Adjuvant systemic therapy for older adults with early-stage breast cancer.
    Pal SK; Mortimer J
    Womens Health (Lond); 2009 May; 5(3):251-62. PubMed ID: 19392611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adjuvant chemotherapy of early stage breast cancer].
    Boér K
    Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA; Afonso SL; Stefano EJ; De Fendi LI; Soares FV
    BMC Cancer; 2007 Aug; 7():153. PubMed ID: 17686164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new millennium for adjuvant therapy in breast cancer.
    Sledge GW
    Oncology (Williston Park); 2008 May; 22(6):598-602; discussion 602-3, 606, 608. PubMed ID: 18561550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy of breast cancer in the older patient.
    Taylor WC; Muss HB
    Oncology (Williston Park); 2010 Jun; 24(7):608-13. PubMed ID: 20669797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P; Guarneri V; Bengala C
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy for early-stage breast cancer.
    McArthur HL; Hudis CA
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):207-22. PubMed ID: 17512445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
    PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in adjuvant therapy for breast cancer.
    Slamon DJ; Romond EH; Perez EA;
    Clin Adv Hematol Oncol; 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. PubMed ID: 16736568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in luminal breast cancers.
    Lim E; Winer EP
    Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
    Goldhirsch A
    Breast; 2013 Aug; 22 Suppl 2():S3-7. PubMed ID: 24074788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in systemic adjuvant therapy of early-stage breast cancer.
    Gradishar WJ; O'Regan RM
    Int J Clin Oncol; 2003 Aug; 8(4):239-47. PubMed ID: 12955580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
    Jahanzeb M
    Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.